News
Latest from Tirecat Health
Milestones, awards and updates on our way to the clinic.
October 2026
Tirecat Health strengthens its team on the road to the clinic
Clinical, product and regulatory expertise join the founders to prepare first-in-human in 2027.
22 September 2026
CSIC joins Tirecat Health as a shareholder
CSIC enters the company by transfer from ICN2: the two institutions behind the RESKIN patents are now both shareholders.
September 2026
Verónica Arévalo joins Tirecat Health through the “la Caixa” Health Innovation Fellowships
Tirecat Health is one of the host companies of the first, pilot edition of the “la Caixa” Health Innovation Fellowships.
March 2025
Tirecat Health wins Transfiere “V Open Deep Tech Start-ups”
Recognised as one of the best deep-tech start-ups in the Spanish ecosystem.
December 2024
RESKIN gets under way: Tirecat Health joins the CaixaImpulse project as linked third party
The “la Caixa” Foundation supports RESKIN with €150,000. As linked third party, Tirecat Health works with ICN2 to turn the results into a product.
August 2024
Tirecat Health is founded: from ICN2–CSIC research to patients
Born in the NANOSFUN group at ICN2, after more than ten years of research on bioinspired catechol chemistry.
In the media
Tirecat in the press
What the media say about Tirecat Health and RESKIN.
Let’s work together
Clinicians, industry partners and investors: we would like to hear from you.
